Loading
Life sciences · Journal article
Pediatric Dermatology · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Acne vulgaris commonly presents in early adolescence with the onset of adrenarche. Treatments for acne in this age group typically mirror those in older adolescents. However, while combined oral contraceptives are an effective hormonal treatment for acne vulgaris in young women, the safety of using a systemic hormonal therapy in younger patients for the management of acne has not been established. Concerns include effects on pubertal development and weight, bone health, cancer risks, and psychiatric effects. This Pediatric Dermatology Research Alliance (PeDRA) consensus project convened a multidisciplinary work group to address these issues and, utilizing a modified Delphi process, to establish best practices regarding the use of combined oral contraceptives in patients under 16 years of age based on available evidence and expert opinion.